On 31 July 2019, a ceremony of laying the time capsule to the building foundation of the Yusuf Hamied Science and Technology Center took place in the Academpharm of the National Academy of Sciences of Belarus. This event marked the start of building the ultra-modern Indian-Belarusian pharmaceutical production.
A delegation of the Indian pharmaceutical company Cipla Limited led by the Chairman of the Board of the company Dr. Yusuf K. Hamied, an honorary member of the National Academy of Sciences of Belarus, participated in the ceremony. The Plenipotentiary Ambassador of the Republic of India to the Republic of Belarus Ms. Sangita Bahadur, the Extraordinary and Plenipotentiary Ambassador of the Republic of Belarus to the Republic of India Andrei Rzheussky, Deputy Minister of Health of the Republic of Belarus Boris Androsyuk and other officials took part in the solemn event.
According to Vladimir Gusakov, Chairman of the NASB Presidium, the new Science and Technology Center is a unique project for the country. “At present, we dismantled warehouses and prepared a construction side to implement the first stage of the project and create an experimental-industrial production of solid dosage forms using innovative technologies. The construction of an industrial building (the second stage of the project) with accommodation at the Yusuf Hamied Science and Technology Center is being completed,” – Vladimir Gusakov said.
As emphasized by Dr. Yusuf Hamied, Chairman of the Board of the Indian pharmaceutical company Cipla Limited, it is important to ensure access to quality medicines at an affordable price. He looked forward to Belarus becoming a center of competence in pharmaceutical production in the region. Belarusian scientists can come to India to learn and master the relevant knowledge and techniques.Creating a new drug production involves the development of new technological methods such as micronization, dry granulation, production of multilayer tablets, etc. It was agreed to localize in Belarus the production of effective and safe drugs to treat socially significant diseases: HIV infections, hepatitis B and C, Alzheimer's disease, pulmonary arterial hypertension. The latest medicines will be produced on a full cycle: from a scientific idea to production. The Indian side invested $1 million in the project.
On 1 August 2019, Dr. Yusuf Hamied spoke to young Belarusian scientists on the development of the country's drug independence.